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Abstract: Background: Antimicrobial resistance (AMR) is a global public health threat with the potential
to cause millions of deaths. There has been a tremendous increase in the use of antimicrobials,
stemming from preventive chemotherapy elimination and control programs addressing neglected
tropical diseases (NTDs). This study aims to identify the frequency of drug resistance for 11 major
NTDs and 20 treatment drugs within a specific period by systematically analyzing the study design,
socio-demographic factors, resistance, and countries of relevant studies. Methods: Adhering to
PRISMA guidelines, we performed systematic reviews of the major 11 NTDs to identify publications
on drug resistance between 2000 and 2016. A quality assessment tool adapted for evaluating
observational and experimental studies was applied to assess the quality of eligible studies. Results:
One of the major findings is that six NTDs have information on drug resistance, namely human
African trypanosomiasis, leishmaniasis, onchocerciasis, schistosomiasis, soil-transmitted helminths,
and trachoma. Many studies recorded resistance due to diagnostic tests, and few studies indicated
clinical resistance. Although most studies were performed in Africa where there is the occurrence of
several NTDs, there was no link between disease burden and locations of study. Conclusions: Based
on this study we deduce that monitoring and surveillance systems need to be strengthened to enable
the early detection of AMR and the mitigation of its global spread.
Keywords: antimicrobial resistance; drug resistance; monitoring; neglected tropical diseases;
surveillance
1. Introduction
In the past two decades, over two billion of the world’s poorest people have been affected by
neglected tropical diseases (NTDs). NTDs are mainly grouped into parasitic, viral, and bacterial
infections in Africa, Asia, and America [1,2]. The widespread and often catastrophic consequences of
NTDs necessitates a global response, prompting organizations such as the United States Centers for
Disease Control and Prevention (CDC), the United Nations (UN), and the World Health Organization
(WHO) to focus on them. The WHO has identified 20 NTDs [3,4], out of which 11 are considered as major
NTDs [5]. The 11 major NTDs studied are Chagas disease, food-borne trematodiasis, human African
trypanosomiasis (HAT), leishmaniasis, leprosy, lymphatic filariasis, onchocerciasis schistosomiasis,
soil-transmitted helminths (STH), taeniasis, and trachoma.
The categorization of these diseases as “neglected” was established by Peter Hotez, Alan Fenwick,
and Alan Fairlamb after the establishment of the Millennium Development Goals (2000) [6]. The WHO
launched its first report on NTDs in 2010, which defined the strategic approaches for reducing the
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burden of identified diseases [7], and provided a “roadmap” revealing the 2015 and 2020 targets for
eradication, elimination, and intensified control.
The two primary methods of interventions for NTDs are preventive chemotherapy and
transmission control (PCT), which covers mass drug administration (MDA) and innovative and
intensified disease management (IDM) [2]. Global strategies and applicable tools are readily available
for PCT [2]. IDM focuses more on NTDs, for which simple tools and treatments are not yet available and
wide-scale prevention cannot be applied [2,8]. According to the WHO, an estimate of 1.7 billion people
in 185 countries needed mass and/or individual treatment and care for NTDs in 2014 [9]. In recent
times, tremendous steps have been taken to curtail NTDs by the Global Network and public–private
partnerships. In 2011, there was a 37% average coverage of PCT for NTDs, but with the involvement of
strong partnerships, the average coverage of PCT increased to 63% in 2016 [10]. PCT-covering MDA
programs have been considered to be effective, in spite of the potential for the development of drug
resistance due to long and continuous usage, which remains a challenge [11]. However, the overall
progress has been uneven. According to Hotez, the WHO has discovered that less than two-thirds of
the global population that needs treatment for NTDs are covered, and the treatment for trachoma and
schistosomiasis is quite inadequate [4,12].
Antimicrobial resistance (AMR) is a global public health threat, and its impacts have the potential
to kill millions of people. It is also a fundamental commercial challenge for private sector companies
because developing new antimicrobials is often expensive and requires long-term proposition [9].
In recent times, AMR has increasingly become a problem because of a tremendous increase in the use of
antimicrobials, which has caused an increase in the rate at which resistance is developing and spreading.
Unfortunately, there are no adequate new antimicrobials to address this situation [13]. The WHO is
committed to developing a global consensus approach to AMR monitoring, with predefined measures
of impact and outcome consistent with the Global Action Plan (GAP) [14]. The Global Antimicrobial
Resistance Surveillance System provides a cornerstone for assessing the spread of AMR, by informing
and monitoring the impact of local, national, and global strategies [15]. Evaluating the impact of
implemented programs and interventions towards the prevention and control of tropical diseases
would be effective, with a surveillance-response system implemented to achieve the maximum amount
of positive health outcomes [16].
Importantly, AMR does not recognize geographic or human/animal species borders. Addressing
the rising threat of AMR requires the “One Health” approach, which addresses human health,
animal health, and the environment. Although the WHO, the Food and Agriculture Organization,
and the World Organization for Animal Health have all taken collective action to minimize the
emergence and spread of AMR through the “Tripartite Collaboration”, there are still limitations with
the agreement [17,18]. Collective action is required in areas of surveillance, infection control, awareness,
and responsible use for successful containment of AMR emergence and spread.
The aim of this study was to identify the frequency of resistance for 11 major NTDs and 20
drugs over a specific period by systematically analyzing the study design, socio-demographic factors,
resistance, and the countries of the studies.
2. Methods
2.1. Protocol Registration
This study was performed according to the Preferred Reporting Items for Systematic Reviews
(PRISMA) statement recommendations. The PRISMA Checklist is summarized in the Supplementary
Information (see Table S1), and the PRISMA statement is also summarized in the Supplementary
Information (see Supplementary Materials S1) [19]. The study protocol was determined prior to
commencement, and it was registered in the PROSPERO-International prospective register of systematic
review with the identification number CRD42016050563 available at: https://www.crd.york.ac.uk/
prospero/#recordDetails.
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2.2. Eligibility Criteria
Studies that assessed resistance in NTDs identified by the WHO were included in this review.
All relevant studies were included irrespective of study design and countries of study. The included
studies were limited to studies performed on human subjects only. Decisions on eligibility were made
by two independent reviewers, all discrepancies and disagreements with respect to study and report
eligibility were resolved through deliberations with a third reviewer.
2.3. Search Strategy
Studies analyzed in this review were identified by searching electronic public databases including:
PubMed (http://www.ncbi.nlm.nih.gov/pubmed) and Scopus (http://www.scopus.com/). The searches
were performed in December 2016 with a limit set for the dates of publications. The search focused on
publications from 2000–2016. A full description of the search terms and search strategy is provided in
Table S2. Efforts were made to download the full text of the included articles, and when not available,
the authors of such articles were contacted. For the unresponsive authors, reminders were sent to allow
for a two-week period before such studies were excluded and classified as “full text not available”.
2.4. Study Selection
Initial eligibility assessments on the retrieved titles and abstracts were performed by two
independent reviewers. Full texts of eligible articles were retrieved and reviewed for inclusion.
The inclusion or exclusion of a study considered conclusive, controversial, or ambiguous by either of the
reviewers was resolved through deliberations between the reviewers. When necessary, disagreements
and discrepancies were resolved by consensus with a third reviewer. Adequate care was taken to
identify more than one article reporting a single study. When this was encountered, the overlap was
identified and resolved.
2.5. Assessment of the Methodological Quality
Based on the recommendations of a number of authors [20–23], the Quality Assessment Tool
for Quantitative Studies (developed by the Effective Public Health Project) [22] was adapted for
evaluating observational and experimental studies. The Assessment Tool contains 19 items in 8 key
domains for evaluating study quality. The eight domains are study design, blinding, selection bias,
withdraws/dropouts, confounders, data collection, data analysis, and reporting.
Using a range of 1 (low risk of bias; high methodological quality) to 3 (high risk of bias; low
methodological quality), an overall rating for each study was determined based on their component
rating. Strong was attributed to those with no weak ratings, and with at least five strong ratings.
Moderate was assigned to those with one weak rating or fewer than five strong ratings. Finally, weak
was attributed to those with two or more weak ratings. A full description of the Quality Assessment
Tool for Quantitative Studies is provided in Supplementary Materials S2.
All included studies were independently assessed for methodological quality by two assessors
(FT and MN). The ratings for each of the eight key domains as well as the total rating from the two
accessors were compared. Consensus was reached on a final rating for all included articles.
3. Results
Using the search terms for each identified major NTD, 1469 articles were screened based on their
titles and abstracts, out of which 815 studies were selected for full-text reading. Based on the selected
studies, two reviewers agreed on 145 decisions, and 37 discrepancies were resolved by discussion
and consensus. A total of 108 studies were included in the final review (see Figure 1). The flowcharts
for each reviewed NTD and the corresponding drugs for treatment are provided in Supplementary
Materials S1.
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observational studies (26 cohort studies, 28 cross-sectional studies, 16 case reports, and 9 case-control 
studies), and 29 articles were experimental studies (21 random experimental studies, and 8 non-
random experimental studies). The most studied NTDs were HAT and schistosomiasis. HAT had the 
highest number of cross-sectional studies, while schistosomiasis had the highest number of cohort 
studies. Study types with respect to the studied NTDs are presented in Figure 2. 
Figure 1. PRISMA flow chart.
Out of 11 NTDs, 6 NTDs had information on AMR, namely HAT, leishmaniasis, onchocerciasis,
schistosomiasis, soil-transmitte helminths, and trachoma. Out of a total of 108 studies, 79 were
observation l studies (26 cohort studies, 28 cross-sectional studies, 16 case reports, and 9 case-control
studies), and 29 articles were experimental studies (21 ra dom experimental studies, a 8 non-random
experimental studies). The most studied NTDs were HAT schistoso iasis. HAT had the highest
number of cross-sectional studies, while schistosomiasis had the highest number of cohort studies.
Study types with respect to the studie NTDs are presented in Figure 2.
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Out of the 108 included studies, 70 studies were conducted in rural settings, 22 studies were 
conducted in urban settings, and 16 studies did not specify their study settings. Studies involving 
both genders were observed in 84 reviewed articles. Studies on males only were observed in 19 
reviewed articles, and 5 studies were on females only. Reviewing the age range of the studies, 45 
studies were conducted on both adults and children, 31 studies involved only adults, and 24 studies 
involved only children. 
With respect to resistance of the reviewed studies, 92% of the articles indicated resistance due to 
diagnostic tests, while 42% of the studies indicated clinical resistance. This indicates a high resistance 
in both laboratory and clinical tests. 
Out of the 28 countries of study, it was observed that most studies were performed in South 
Sudan, Tanzania, Kenya, Cameroon, Uganda, Cote d’Ivoire, the Democratic Republic of Congo 
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Figure 2. Prevalence of the study types of diseases. HAT: human African trypanosomiasis.
HAT studies had 31% cross-sectional studies and 20% case reports. Schistosomiasis studies had
58% cohort studies and 32% cross-sectional studies.
Out of the 108 included studies, 70 studies were conducted in rural settings, 22 studies were
conducted in urban settings, and 16 studies did not specify their study settings. Studies involving both
genders were observed in 84 reviewed articles. Studies on males only were observed in 19 reviewed
articles, and 5 studies were on females only. Reviewing the age range of the studies, 45 studies were
conducted on both adults and children, 31 studies involved only adults, and 24 studies involved
only children.
With respect to resistance of the reviewed studies, 92% of the articles indicated resistance due to
diagnostic tests, while 42% of the studies indicated clinical resistance. This indicates a high resistance
in both laboratory and clinical tests.
Out of the 28 countries of study, it was observed that most studies were performed in South
Sudan, Tanzania, Kenya, Cameroon, Uganda, Cote d’Ivoire, the Democratic Republic of Congo (DRC),
Angola, and India. There was no link between the countries of studies and disease burden as presented
in Figures 3–8.
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Table 1. The characteristics of reviewed NTDs and their treatments.
Data
Neglected Tropical Diseases (NTDs)
Human African Trypanosomiasis
(Studied Drugs)
Leishmaniasis
(Studied Drug)
Onchocerciasis
(Studied
Drug)
Schistosomiasis
(Studied
Drug)
Soil-Transmitted
Helminths
(Studied Drugs)
Trachoma
(Studied
Drug)
Eflornithine Melarsoprol Pentamidine Suramin Amphotericin B Ivermectin Praziquantel Albendazole Mebendazole Azithromycin
Study
Design
Experimental 2 6 1 1 5 3 1 2 2 6
Observational 8 14 12 7 7 4 18 3 2 4
Study
Settings
Not Specified 4 3 3 2 0 0 1 2 0 1
Rural 4 17 6 5 2 7 13 3 4 9
Urban 2 0 4 1 10 0 5 0 0 0
Gender
Both 7 18 12 3 7 4 14 5 4 10
Female only 1 0 0 0 1 0 3 0 0 0
Male only 2 2 1 5 4 3 2 0 0 0
Age Range
Adults 6 8 3 5 5 4 6 0 0 0
Children 0 0 1 1 1 0 7 5 3 8
Both 4 12 8 2 6 3 6 0 1 2
Resistance
by Tests
YES 9 18 13 8 9 6 18 5 4 9
NO 1 2 0 0 3 1 1 0 0 1
Clinical
Resistance
YES 6 6 7 7 10 0 4 1 0 4
NO 64 14 6 1 2 7 15 4 4 6
Countries of Study
Angola,
Cote
d’Ivoire,
Democratic
Republic of
Congo,
Germany,
South
Sudan,
Uganda,
and
Western
Australia
Angola,
Cameroon, Cote
d’Ivoire, Central
African Republic
(CAR),
Democratic
Republic of
Congo,
Equatorial
Guinea, Kenya,
South Sudan,
Tanzania, and
Uganda
Angola,
Central
African
Republic
(CAR),
Cote
d’Ivoire,
Democratic
Republic of
Congo,
Equatorial
Guinea,
South
Sudan, and
Uganda
Belgium,
Cameroon,
Democratic
Republic
of Congo,
India,
England,
Malawi
and
Tanzania
Brazil, China,
Ethiopia, India,
Sudan, and Kenya
Cameroon,
Ghana, and
South Sudan
China, Cote
d’Ivoire,
Egypt,
Kenya, South
Sudan,
Tanzania,
Uganda, and
Zambia
Brazil,
Cambodia,
Cameroon,
Ethiopia,
Haiti, India,
Indonesia,
Kenya,
Panama,
Tanzania,
and
Vietnam
Indonesia
and
Tanzania
Ethiopia,
Nepal, and
Tanzania
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Methodological Quality Assessment
In the overall assessment, the methodological quality of six reviewed studies were rated as strong,
and 23 and 79 articles were rated as moderate and weak, respectively (see Table S3 for the full details of
the quality assessment results). There were 20 reviewed studies rated as weak for their data collection
because the authors did not provide sufficient information on the validity or reliability of their methods
of collection. There were 40 articles rated as moderate, and 42 articles rated as strong. With respect to
confounders, 37 articles were rated as weak, and 18 and 52 articles were rated as moderate and strong,
respectively. Based on the data analysis of each reviewed study, 63.3% of the reviewed articles were
rated as strong, while 14.3% and 22.4% were rated as moderate and weak, respectively. The reporting
quality of the reviewed articles was also analyzed. Out of the 108 articles included, 59.3% were rated
as strong, and 28.7% and 12.0% were rated as moderate and weak, respectively.
4. Discussion
This study reviewed 11 out of the 20 NTDs identified by the WHO as the most important NTDs [5]
which have specific drugs for treatment.
The major finding was that only six NTDs of those reviewed had information on AMR, namely,
HAT, leishmaniasis, onchocerciasis, schistosomiasis, soil-transmitted helminths, and trachoma, while
there was a deficiency of data to determine the magnitude and scope of resistance in the other reviewed
NTDs. Moreover, it could be inferred that data deficiencies were from countries without surveillance
or as a result of under-reporting in some countries. One of the main objectives of GAP-AMR is to
ensure that there is the successful treatment and prevention of infectious diseases with effective and
safe medicines that are quality assured and accessible to people at risk [15,25]. However, there is no
harmonized system in place to standardize the collection of AMR data to facilitate a comprehensive
purview of the global occurrence of AMR [14,15]. Even though PCT and MDA programs are currently
effective in mitigating the morbidity of NTDs and improving the quality of life in the most affected
countries [26], there is insufficient information on the program monitoring the effects of PCT and
MDA. For AMR to be effectively and efficiently monitored, the collection of surveillance data is
paramount to inform and estimate the AMR burden of NTDs. Following a recommendation by
the Working Group on Monitoring and Evaluation of the Strategic and Technical Advisory Group
for NTDs, the integrated NTD database developed by the WHO to improve the evidence-based
planning and management of NTD programs at the national and sub-national levels does not contain
information on AMR [27]. Immersed efforts are required to ensure that treatments are implemented
efficiently and that monitoring and surveillance tools are improved [28]. It has been observed and
argued that an effective surveillance-response system is a core feature of gaining reliable information
on the prevalence, incidence, and burden of diseases which is essential for the prevention, control,
and elimination of NTDs [16]. The health systems in countries where NTDs are endemic are often
constrained by insufficient funding, limited human resources, insufficient management, and poor
governance, which have impacts on the NTDs in these regions [29].
The number of studies that indicated resistance through diagnostic tests was considerably high
in the reviewed studies. This indicates that accurate disease diagnoses are essential for appropriate
and effective treatments, as well as disease control [30]. The Neglected Infectious Diseases Diagnosis
consortium has been working to improve diagnostic approaches for different clinical syndromes in
low-resource settings where NTDs are prevalent [30]. Moreover, this review indicates that clinical
resistance was less than half in the studies. This suggests that observing people is not enough, and
there is an urgent need for accessible diagnostic technologies for AMR [31]. It has been observed that
the effect of PCT is weak compared to the original framework, and this may be as a result of increased
drug pressure due to the mechanism of drug resistance. Drug efficacy monitoring is important
for control programs based on PCT in order to support the correct use of antimicrobials (dosage,
frequency, combinations), by ensuring the implementation of successful mitigation strategies [32,33].
Though pharmaceutical research and development had historically neglected the infectious diseases,
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there has been a recent increase in collaborative clinical research addressing the NTDs health needs
of low-to-middle-income countries through therapeutic and diagnostic trials [34]. Furthermore, the
Good Clinical Practices codes of the WHO and the International Conference of Harmonization provide
globally applicable standards for designing, conducting, recording, and reporting clinical trials [34].
The respondents of a survey were of the opinion that drug resistance is a major challenge for the
elimination of NTDs [35]. This opinion aligns with the experience of the global health community
on malaria, in which resistance was found to have emerged after the mass distribution of medicated
salts [36]. AMR has been recorded in malaria treatment, due to inappropriate, badly executed, or poorly
accepted MDA. However, effective MDA with a good adherence routine can prevent the emergence of
AMR [37]. The review findings also show that there was more information on the individual usage of
the drugs compared to MDA. Studies on the PCT-MDA of NTDs like onchocerciasis, schistosomiasis,
and soil-transmitted helminths had less information on their MDA programs. The issue of the low
coverage of MDA programs is not a surprise, as it is a recognized challenge as the 2020 deadline for
most NTDs approaches.
This review also indicates that some studies were conducted in countries where NTDs are
prevalent but with less information on their AMR. Moreover, there are countries with high prevalence
of NTDs (e.g., leishmaniasis is highly prevalent in Afghanistan, Yemen, Pakistan; onchocerciasis in
DRC, and Nigeria), but there were no studies in this review performed in these countries. This might
be as a consequence of either inefficient monitoring and surveillance tools or the political instability in
these countries [38].
The overall description of the study settings of this review shows that most studies were conducted
in the rural areas. Ponte-Sucre et al. highlighted that poor socioeconomic conditions are one of the
fundamental contributory factors to AMR [26]. This concurs with the fact that these diseases are
prevalent amongst the poorest populations of the world, putting an estimated 2.7 billion people at
risk [39]. In spite of the international funding and support offered by the WHO and the existence of
philanthropic organizations to fight NTDs in these at-risk poor populations, the public health burden
and the challenges facing programs to achieve sustained control and ultimate elimination of major
NTDs are still enormous [16]. Failure to tackle AMR threatens the attainment of various Sustainable
Development Goals (SDGs), such as those on poverty reduction, reduced inequalities, clean water,
economic growth, food security, and sanitation [18].
The burden of NTDs can be taken up by long-term capacity building and health-system-wide
reforms, which will depend on health systems stepping up measures to meet the demands for services
as part of their transition towards Universal Health Coverage (UHC). Therefore, there is much that
NTD programs have to share with national health systems as they strive towards UHC [28], in order
to improve monitoring and surveillance tools, coupled with effective reporting systems towards the
progress 2020 roadmap targets for NTDs.
In identifying the resistance through a systematic review, data extraction and compilation are
prone to bias. As a result, efforts were made to identify and screen published literature with a specific
search query. Moreover, some relevant studies might have been excluded due to the search criteria
narrowing publication dates from 2000–2016 due to both inaccessibility and lack of full text availability.
Additionally, all studies with incomplete information were excluded. This review relied completely on
published literature where grey literature and studies with minimal or negative results may not have
been included, resulting in publication bias.
5. Conclusions
As 2020 approaches, it is essential to foster national surveillance systems and harmonize global
standards that estimate the extent of AMR globally. The global community is committed to reducing
the impact of NTDs on the poorest populations through the administration of PCT and medical care to
people suffering from chronic manifestations of these NTDs. Presently, there is a global scale-up in
PCT and drug donations through official development assistance and philanthropies, and hence there
Int. J. Environ. Res. Public Health 2019, 16, 1925 12 of 14
is an urgent need for effective and efficient data monitoring and national surveillance systems that will
enable the early detection of AMR and the mitigation of its global spread.
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